Geoffrey S. Kim

发表

U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.

R. Pazdur, Geoffrey Kim, Lijun Zhang, 2015, The oncologist.

U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapyâ•’NaÃ ̄ve Metastatic Castrationâ•’Resistant Prostate Cancer

R. Pazdur, Geoffrey Kim, Lijun Zhang, 2015 .

U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Na¨ ı ve Metastatic Castration-Resistant Prostate Cancer

R. Pazdur, Geoffrey Kim, Lijun Zhang, 2015 .

Decoding kinase-adverse event associations for small molecule kinase inhibitors

Amy McKee, Todd R. Palmby, Geoffrey Kim, 2022, Nature Communications.

Proteomics and ovarian cancer: integrating proteomics information into clinical care.

E. Kohn, Geoffrey Kim, I. Giuroiu, 2010, Journal of proteomics.

Successes and Challenges of PARP Inhibitors in Cancer Therapy

Amy McKee, R. Pazdur, Geoffrey Kim, 2015, Front. Oncol..

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

Liang Zhao, Hui Zhang, Richard Pazdur, 2015, Clinical Cancer Research.

FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs

Sarah E. Dorff, Amy McKee, R. Pazdur, 2016, Clinical Cancer Research.

Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary

C. Garnett, R. Pazdur, Y. Moon, 2012, Clinical Cancer Research.

Enrollment of older adults on oncology trials: An FDA perspective.

R. Pazdur, J. Beaver, H. Singh, 2017, Journal of geriatric oncology.

US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments.

K. Goldberg, Amy McKee, R. Pazdur, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the U.S. Food and Drug Administration.

L. Fashoyin-Aje, R. Pazdur, Geoffrey Kim, 2017 .

A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety.

S. Steinberg, E. Kohn, Jung-Min Lee, 2013, Molecular and clinical oncology.

L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer

E. Kohn, Minshu Yu, Geoffrey Kim, 2012, Journal of cellular and molecular medicine.

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation–Associated Advanced Ovarian Cancer

S. J. Schrieber, Chao Liu, Richard Pazdur, 2017, Clinical Cancer Research.

FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation

Justin C. Earp, Amy McKee, R. Pazdur, 2014, Clinical Cancer Research.

U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non–Small Cell Lung Cancer

S. Khozin, K. Goldberg, R. Pazdur, 2017, Clinical Cancer Research.

Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials

P. Keegan, R. Pazdur, Geoffrey Kim, 2015, Clinical Cancer Research.

21st Century Cardio-Oncology

J. Moslehi, Todd R. Palmby, T. Force, 2016, JACC. Basic to translational science.

FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers.

R. Pazdur, Geoffrey Kim, G. Blumenthal, 2016 .

Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis

G. Helmlinger, Geoffrey Kim, K. Peskov, 2020, Oncoimmunology.

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer

R. Pazdur, R. Charlab, Todd R. Palmby, 2015, Clinical Cancer Research.

FDA analysis of treatment beyond disease progression disease (PD) in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab vs. everolimus.

R. Pazdur, Geoffrey Kim, Lijun Zhang, 2016 .

U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma

Amy McKee, R. Pazdur, Todd R. Palmby, 2016, Clinical Cancer Research.

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy

K. Goldberg, R. Pazdur, Todd R. Palmby, 2017, The oncologist.

Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms

Martha Donoghue, P. Keegan, R. Pazdur, 2016, Clinical Cancer Research.

Regulatory watch: From big data to smart data: FDA's INFORMED initiative

Sean Khozin, Richard Pazdur, S. Khozin, 2017, Nature Reviews Drug Discovery.

Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials—Response

Martha Donoghue, P. Keegan, R. Pazdur, 2016, Clinical Cancer Research.

Regulatory considerations on endpoints in ovarian cancer drug development

Amy McKee, R. Pazdur, Geoffrey Kim, 2017, Cancer.

Clinical Development of Cancer Drugs in Combination With External Beam Radiation Therapy: US Food and Drug Administration Perspective.

R. Pazdur, Geoffrey Kim, P. Kluetz, 2017, International journal of radiation oncology, biology, physics.

Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome

E. Kohn, Junbai Wang, B. Davidson, 2012, Cancer.

Proteomic Profiling in Ovarian Cancer

E. Kohn, Geoffrey Kim, L. Minig, 2009, International Journal of Gynecologic Cancer.

FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti‐Angiogenic Therapy and Exploratory Predictive Biomarker Analysis

R. Pazdur, Geoffrey Kim, Lijun Zhang, 2017, The oncologist.

FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

Amy McKee, R. Pazdur, Todd R. Palmby, 2016, Clinical Cancer Research.

Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle

P. Jänne, A. Shaw, Amy McKee, 2016, Clinical Cancer Research.

FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper.

B. Monk, Amy McKee, R. Pazdur, 2017, Gynecologic oncology.

Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition

M. Bertagnolli, L. Fashoyin-Aje, R. Pazdur, 2022, Nature Medicine.

FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs

Amy McKee, R. Pazdur, R. Charlab, 2016, Clinical Cancer Research.

Challenges and Opportunities in Dose Finding in Oncology and Immuno‐oncology

D. Hyman, Geoffrey Kim, Yan Ji, 2018, Clinical and translational science.

FDA analysis of patients with baseline autoimmune diseases treated with PD-1/PD-L1 immunotherapy agents.

R. Pazdur, Geoffrey Kim, H. Singh, 2017 .